DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
MARAC Advisory Statement Regarding SCD Patients during the time of “Reopening” the U.S. Economy
May 14, 2020—On Thursday April 16, 2020, the U.S. Coronavirus Taskforce provided recommendations on reopening the economy, giving states specific metrics, policies, and benchmarks regarding case load, hospital preparedness and testing capability with the goal of reopening on May 1. In order to proceed through the entire process, states must complete a two-week pre-phase, and then complete a two-week gating period with no evidence of rebound infections between each of the phases.
During the first two phases, the taskforce recommended that all vulnerable individuals remain at home and that everyone should work from home if they are able to do so. It also concluded that employers should make special accommodations for vulnerable individuals at work if working from home is not possible. During the last phase, vulnerable individuals could resume working normally, with physical distancing while in public places.
It is the position of the Medical and Research Advisory Committee (MARAC) of the Sickle Cell Disease Association of America that patients with sickle cell disease are considered vulnerable individuals based on American Society of Hematology (ASH) COVID19 guidelines.
Related Content
-
news & eventsSickle Cell Disease and COVID-19: An Outline to Decrease Burden and Minimize Morbidity (Adapted for Sub-Saharan Afri...April 1, 2020- Sickle cell disease (SCD)...
-
news & eventsInformation About COVID-19 for Sickle Cell Disease PatientsCOVID-19, short for coronavirus disease ...
-
videos & visualsYou Should Get a COVID-19 Vaccine – Frenchhttps://www.youtube.com/watch?v=5DMfiyA0...
-
education & researchCOVID-19 and Sickle Cell Disease: Frequently Asked QuestionsHow do people with sickle cell disease (...
-
news & eventsMARAC Statement: Update About COVIDThe worldwide pandemic of COVID-19 (SARS...
-
news & eventsSCDAA COVID-19 Emergency Fund CampaignThe Sickle Cell Disease Association of A...
-
videos & visualsYou Should Get a COVID-19 Vaccine – Japanesehttps://www.youtube.com/watch?v=W8i01thN...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.